Mark Johnson | VP, IR |
Stephen Davis | CEO & Director |
Brendan Teehan | EVP, COO & Head, Commercial |
Kathie Bishop | SVP and Head, Rare Disease & External Innovation |
Srdjan Stankovic | President |
Mark Schneyer | EVP & CFO |
Jeff Hung | Morgan Stanley |
Neena Bitritto-Garg | Citi |
Ritu Baral | Cowen and Company |
Salveen Richter | Goldman Sachs |
Jay Olson | Oppenheimer |
Alex Nackenoff | Raymond James & Associates |
Marc Goodman | SVB Securities |
Gregory Renza | RBC Capital Markets |
Yatin Suneja | Guggenheim Securities |
Charles Duncan | Cantor Fitzgerald |
Sumant Kulkarni | Canaccord Genuity |
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Third Quarter 2022 Financial Results Conference Call. My name is Gigi, and I will be your coordinator for today. [Operator Instructions]. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.